Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 14 Urinary Bladder Neoplasms 11 Breast Neoplasms 11 Neoplasm Metastasis 10 Carcinoma, Renal Cell 8 Carcinoma, Merkel Cell 8 Neoplasms 7 Colorectal Neoplasms 7 Head and Neck Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Neuroendocrine Tumors 4 Leukemia, Myeloid, Acute 4 Urethral Neoplasms 3 Ureteral Neoplasms 3 Skin Neoplasms 3 Prostatic Neoplasms 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Neuroendocrine 3 Carcinoma, Hepatocellular 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Penile Neoplasms 2 Pancreatic Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasm, Residual 2 Mesothelioma, Malignant 2

Interventions

Cyclophosphamide 165 fludarabine phosphate 110 Peripheral Blood Stem Cell Transplantation 94 Mycophenolic Acid 88 Whole-Body Irradiation 81 Etoposide 81 Tacrolimus 73 Busulfan 68 Melphalan 67 Filgrastim 66 fludarabine 62 Radiotherapy 56 Doxorubicin 54 Cyclosporine 54 Rituximab 50 Brentuximab Vedotin 48 Antilymphocyte Serum 47 Granulocyte Colony-Stimulating Factor 42 Vinblastine 41 Methotrexate 38 Dacarbazine 37 Cytarabine 35 Gemcitabine 34 Nivolumab 30 Bleomycin 29 Carmustine 28 Vincristine 25 Prednisone 25 Sirolimus 24 Bendamustine Hydrochloride 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hodgkin Disease × avelumab × Clear all

NCT03617666 2023-12-12

AVENuE

University College, London

Phase 2 Unknown

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡